期刊文献+

气相色谱法同时测定替格瑞洛片中14种残留溶剂

Determination of 14 residual solvents in the drug of ticagrelor tablets by GC
下载PDF
导出
摘要 为建立同时测定替格瑞洛片中14种残留溶剂的方法,采用DB-624(75 m×0.53 mm×3μm)毛细管气相色谱柱,柱流速5.0 mL/min,FID检测器,进样口温度200.0℃,检测器温度250.0℃,分流比为10∶1,正丙醇为内标,内标法定量测定替格瑞洛片中异辛烷、正庚烷、甲苯、N,N-二异丙基乙胺、甲醇、乙醇、乙腈、异丙醇、甲基叔丁基醚、乙酸乙酯、四氢呋喃、二氧六环、乙二醇和二氯甲烷14种溶剂的残留量。结果显示:各成分之间能有效分离,在1.6~124.9μg/mL线性范围内各个化合物线性关系良好(r≥0.9995);回收率为73.6%~122.1%,RSD(n=6)为0.4%~12.2%;定量限为1.0~20.8μg/mL。该方法操作简便、快速、灵敏、高效,可为替格瑞洛片质量标准的提高提供依据。 To establish a GC method for determination of 14 residual organic solvents in Ticagrelor tablets,Isooctane,n-heptane,toluene,N,N-Diisopropylethylamine,methanol,ethanol,acetonitrile,isopropanol,methyl tert-butyl ether,ethyl acetate,tetrahydrofuran,dioxane,ethylene glycol and dichloromethane were determined on DB-624(75 m×0.53 mm×3μm),with the column flow rate of 5 mL/min,FID detector,injection port temperature 200℃,detector temperature 250℃,split ratio 10∶1,n-propanol quantified as internal standard.Results show that the components can be effectively separated,and have a good linear relationship(r≥0.9995)in each linear range(1.6~124.9μg/mL),the average recoveries were 73.6%~122.1%,with RSDs(n=6)of 0.4%~12.2%,The limit of quantification was 1.0~20.8μg/mL.The method is easy,rapid,sensitive,and efficient,and provides a basis for quality standard improvement of ticagrelor tablets.
作者 曹桂红 王兴宁 刘璐 黄春青 许波 CAO Guihong;WANG Xingning;LIU Lu;HUANG Chunqing;XU Bo(Guizhou Food and Drug Inspection Institute,Guiyang,Guizhou 550004,China;Guiyang Customs Comprehensive Technology Center,Guiyang,Guizhou 550081,China)
出处 《贵州师范大学学报(自然科学版)》 CAS 2022年第4期23-26,48,共5页 Journal of Guizhou Normal University:Natural Sciences
基金 2021国家药品抽检项目(编号:85)。
关键词 替格瑞洛片 残留溶剂 气相色谱法 ticagrelor tablet residual solvent GC
  • 相关文献

参考文献8

二级参考文献114

  • 1薛娜,张恺,杜玉民,刘伟娜.手性药物的药理学及其分离测定研究进展[J].河北医科大学学报,2009,30(7):753-756. 被引量:3
  • 2Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.- The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2011,32(23) : 2999-3054.
  • 3Arora RR, Rai F. Antiplatelet intervention in acute coronary syndrome[J]. Am J Ther, 2009, 16 (5) : e29-e40.
  • 4Wiviott SD, Braunwald E, McCabe CH, et al. Pra- sugrel versus clopidogrel in patients with acute cor- onary syndromes[J]. N Engl J Med, 2007,357 (20) : 2001-2015.
  • 5Husted S, van Giezen JJ. Ticagrelor: the first re- versibly binding oral P2Y12 receptor antagonist [J]. Cardiovasc Ther,2009,27(4) : 259-274.
  • 6Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11) : 1045- 1057.
  • 7Brilinta (ticagrelor) Tablets: A P2Y(12) platelet inhibitor indicated to reduce the rate of thromboticcardiovascular events in patients with acute coro- nary syndrome (ACS)[J]. P T, 2012,37(4 section 2) : 4-18.
  • 8Teng R, Butler K. Pharmacokinetics, pharmacody- namics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y (12) receptor antagonist, in healthy subjects[J]. Eur J Clin Pharmacol,2010,66(5) : 487-496.
  • 9Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ti- cagrelor in healthy subjects[J] Drug Metab Dispos, 2010,38(9) : 1514-1521.
  • 10Storey RF, Husted S, Harrington RA, et al. Inhi- bition of platelet aggregation by AZD6140, a re- versible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2007,50 (19) : 1852-1856.

共引文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部